AUR-101 is under clinical development by Aurigene Discovery Technologies and currently in Phase II for Ankylosing Spondylitis (Bekhterev’s Disease). According to GlobalData, Phase II drugs for Ankylosing Spondylitis (Bekhterev’s Disease) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AUR-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUR-101 overview
AUR-101 is under development for the treatment of moderate-to-severe chronic plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. The drug candidate is administered through oral route in the form of tablet. It is a small molecule act by targeting retinoid related orphan receptor gamma (ROR-gamma). It was also under development for the treatment of cancer, inflammatory diseases (Th17 mediated diseases) including asthma,encephalomyelitis and rheumatoid arthritis.
Aurigene Discovery Technologies overview
Aurigene Discovery Technologies (Aurigene), a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of products for immunobiology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.
For a complete picture of AUR-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
